LXRX Lexicon Pharmaceuticals Inc: Accounting Value per Share

Graphic logo of Lexicon Pharmaceuticals (LXRX)

Lexicon Pharmaceuticals (LXRX) develops innovative molecules to combat cardiological pathologies and diabetes, bypassing standard therapy methods. This price chart confirms the impact on quotes of limited pricing power over medications due to insurance company requirements, with the indicator standing at 0.39. Simultaneously, the business is implementing bioethical principles and reducing harmful emissions at its research centers.

Lexicon Pharmaceuticals Inc (LXRX): Share Book Value from 07/04/2022 to 10/27/2026

lexpharma.com - analytical breakdowns and key metrics (LXRX)

- price and consensus price forecast:
Price Chart Lexicon Pharma|LXRX - Fair Value Consensus
- market capitalization data:
Market Valuation Lexicon Pharmaceuticals, Inc.|LXRX - Business Value
- book capitalization data:
Net Assets per Single Share Lexicon Pharmaceuticals|LXRX - Net Asset Value|Market Capitalization to Book Value Ratio lexpharma.com|LXRX - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Lexicon Pharmaceuticals|LXRX - Long-Term Debt to Capital|Short-Term Debt to Equity Lexicon Pharmaceuticals, Inc.|LXRX - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Lexicon Pharmaceuticals, Inc.
Fundamental company valuation:Lexicon Pharma - LXRX
Manufactured products of Lexicon Pharmaceuticals, Inc.

For Lexicon Pharmaceuticals (LXRX), which implements AI in molecule screening for diabetes therapy, the book value per common share reflects the actual capitalization of tangible and intangible assets. This indicator is calculated as the difference between total assets and liabilities divided by the number of shares, allowing an investor to assess the asset's intrinsic value and its resilience to market volatility.

Competitors of Lexicon Pharmaceuticals (LXRX)

Net Assets per Single Share Ascendis Pharma Inc. (ASND)|Madrigal Corp (MDGL) - Accounting Value of a Share|Accounting Value per Share Corcept Therapeutics|RYTM (rhythmtx.com) - Equity per Share|Net Assets per Single Share Akero AKRO|Share Book Value Metsera, Inc.|MoonLake Pharma (MLTX) - Book Value per Share|Accounting Value of a Share Crinetics Corp (CRNX)|Book Value per Share NAMS (NewAmsterdam Pharma)|soleno.life - Book Value per Share|Net Assets per Single Share Amicus Therapeutics, Inc. (FOLD)|ETNB: Accounting Value of a Share|AGIO (Agios Pharmaceuticals Inc) - Net Assets per Single Share|Structure Corp (GPCR) - Accounting Value per Share|MDXG (MiMedx Group, Inc.) - Book Value per Share|Book Value per Share rezolutebio.com (RZLT)|MBX Biosciences (MBX) - Accounting Value per Share|Accounting Value of a Share ALT (Altimmune Inc)|Aardvark Therapeutics Corp - Net Assets per Single Share|Accounting Value per Share Sagimet Biosciences Inc SGMT|BIOA (BioAge Labs, Inc.) - Book Value per Share|biomeafusion.com (BMEA) - Net Asset Value per Share|QNCX - Accounting Value per Share|Fractyl Health Inc. (GUTS) - Book Price of a Share|VTVT (vTv Therapeutics, Inc.) - Book Value per Share|Book Value per Share Agape ATP Corp.|Book Value per Share Pluri Inc. (PLUR)|Net Assets per Single Share SYBX (synlogictx.com)|LPCN: Net Assets per Single Share|Matinas BioPharma Holdings, Inc. - Net Asset Value per Share|SPRB - Net Assets per Single Share|GLTO - Net Assets per Single Share|Carmell Corporation - Book Value per Share|LUMO (lumos-pharma.com) - Net Assets per Share|ONVO: Net Assets per Single Share|Net Assets per Share RDUS